B. Riley Wealth Advisors Inc. Grows Stock Position in Illumina, Inc. (NASDAQ:ILMN)

B. Riley Wealth Advisors Inc. boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 66.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,973 shares of the life sciences company’s stock after buying an additional 4,797 shares during the quarter. B. Riley Wealth Advisors Inc.’s holdings in Illumina were worth $1,582,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Tidal Investments LLC grew its holdings in Illumina by 38.0% during the 3rd quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock valued at $580,000 after purchasing an additional 1,226 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Illumina during the third quarter valued at approximately $772,000. Sanctuary Advisors LLC grew its stake in shares of Illumina by 2.0% during the third quarter. Sanctuary Advisors LLC now owns 22,778 shares of the life sciences company’s stock valued at $3,192,000 after buying an additional 450 shares during the last quarter. M&T Bank Corp raised its holdings in shares of Illumina by 3.4% in the third quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company’s stock worth $7,091,000 after buying an additional 1,769 shares during the period. Finally, TD Private Client Wealth LLC lifted its stake in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.4 %

NASDAQ ILMN opened at $144.40 on Tuesday. The firm has a market cap of $22.90 billion, a PE ratio of -14.50 and a beta of 1.11. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a 50 day moving average price of $144.35 and a 200 day moving average price of $128.93.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.33 earnings per share. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their price objective on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. UBS Group raised their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $165.95.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.